Hering Justin, Garrean Sean, Dekoj Thomas R, Razzak Anthony, Saied Abdul, Trevino Jose, Babcock Tricia A, Espat N Joseph
Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, USA.
Ann Surg Oncol. 2007 Dec;14(12):3620-8. doi: 10.1245/s10434-007-9556-8. Epub 2007 Sep 26.
Pancreatic cancer-gemcitabine (GEM) chemoresistance has been demonstrated to be associated with enhanced NF-kB activation and antiapoptotic protein synthesis. The well-known capacity of omega-3 fatty acids (n-3 FAs) to inhibit NF-kB activation and promote cellular apoptosis has the potential to restore or facilitate gemcitabine chemosensitivity.
Four pancreatic cancer cell lines (MIA PaCa-2, BxPC-3, PANC-1, and L3.6), each with distinct basal NF-kB and differing GEM sensitivity profiles, were administered: 100 uM of (1) n-3FA, (2) n-6FA, (3) GEM, (4) n-3FA + GEM, or (5) n-6FA + GEM for 24 and 48 hours. Proliferation was assessed using the WST-1 assay. To define the mechanism(s) of altered proliferation, electron mobility shift assay for NF-kB activity, western blots of phoshoStat3, phosphoIkappaB, and poly(ADP-ribose) polymerase (PARP) cleavage were performed in the MIA PaCa-2 cell line.
All cell lines demonstrated a time/dose-dependent inhibition of proliferation in response to n-3FA. For MIA PaCa-2 cells, n-3FA and n-3FA + GEM treatment resulted in reduction of I-kB phosphorylation and NF-kB activation when compared with n-6FA control. n-3FA and combination treatment also significantly decreased Stat3 phosphorylation, whereas GEM alone had no effect. n-3FAs and n-3FA + GEM groups demonstrated increased PARP cleavage, mirroring NF-kB activity and Stat3 phosphorylation.
n-3 FA treatment is specifically associated with inhibition of proliferation in these four pancreatic cell lines irrespective of varied gemcitabine resistance. An experimental paradigm to screen for potential contributory mechanism(s) in altered pancreatic cancer cellular proliferation was defined, and using this approach the co-administration of n-3 FA with GEM inhibited GEM-induced NF-kB activation and restored apoptosis in the MIA PaCa-2 cell-line.
胰腺癌对吉西他滨(GEM)的化疗耐药已被证明与NF-κB激活增强和抗凋亡蛋白合成有关。ω-3脂肪酸(n-3 FAs)具有抑制NF-κB激活和促进细胞凋亡的众所周知的能力,有可能恢复或促进吉西他滨的化疗敏感性。
对四种具有不同基础NF-κB和不同吉西他滨敏感性特征的胰腺癌细胞系(MIA PaCa-2、BxPC-3、PANC-1和L3.6)分别给予:100 μM的(1)n-3FA、(2)n-6FA、(3)吉西他滨、(4)n-3FA +吉西他滨或()n-6FA +吉西他滨,处理24小时和48小时。采用WST-1法检测细胞增殖。为了确定增殖改变的机制,在MIA PaCa-2细胞系中进行了NF-κB活性的电泳迁移率变动分析、磷酸化Stat3、磷酸化IκB和聚(ADP-核糖)聚合酶(PARP)裂解的蛋白质免疫印迹分析。
所有细胞系对n-3FA均表现出时间/剂量依赖性的增殖抑制。对于MIA PaCa-2细胞,与n-6FA对照组相比,n-3FA和n-与单独使用吉西他滨相比,n-3FA和n-3FA +吉西他滨处理导致I-κB磷酸化和NF-κB激活减少。n-3FA和联合处理也显著降低了Stat3磷酸化,而单独使用吉西他滨则没有效果。n-3FAs和n-3FA +吉西他滨组显示PARP裂解增加,反映了NF-κB活性和Stat3磷酸化。
无论吉西他滨耐药情况如何,n-3 FA处理均与这四种胰腺癌细胞系的增殖抑制特异性相关。定义了一种筛选胰腺癌细胞增殖改变中潜在促成机制的实验范式,并且使用这种方法,n-3 FA与吉西他滨联合给药抑制了吉西他滨诱导的NF-κB激活并恢复了MIA PaCa-2细胞系中的细胞凋亡。